Avian Pasteurella multocida Vaccine, Inactivated (Strain 1502) Veterinary Grade API is an inactivated whole-cell antigen concentrate derived from a defined avian isolate of Pasteurella multocida. The material is intended solely as a formulation intermediate for downstream veterinary dosage presentations including tablets, injections, capsules, powders, granules, premix, and solutions. It is not a finished immunological product; the final presentation must be completed with an appropriate adjuvant, buffer, preservative system, and container-closure configuration under the relevant biological product authorization.

The API is available as a lyophilized powder or chilled liquid concentrate. Liquid concentrates are normally held at 2–8 °C; lyophilized powder is normally stored at −20 °C unless the batch certificate specifies otherwise. The strain is maintained under a seed-lot system, and each production batch is inactivated to a validated endpoint. Inactivation is confirmed by at least two consecutive subcultures in media capable of supporting Pasteurella multiplication, and residual inactivating agent is reported. The antigenic mass is standardized by cell dry weight, opacity units, or antigen-capture ELISA against a reference antigen standard. Because the API contains whole bacterial cells, it carries lipopolysaccharide, outer membrane proteins, and other natural components; endotoxin content is therefore not zero and must be controlled for the intended dose form.

Cold-chain interruption and freeze-thaw cycling are common failure modes observed in pilot-scale handling of inactivated bacterial antigens. A liquid concentrate that freezes unintentionally can disrupt cell membranes and release intracellular proteases; upon thawing, the suspension may separate into an upper lipid-rich layer and a lower aggregated cell layer. Such a batch should not be returned to process without revalidation, because potency loss is not always detected by visual inspection. For lyophilized API, moisture ingress through damaged stoppers or incomplete crimping is the principal stability risk. Headspace moisture should be monitored by near-infrared spectroscopy or Karl Fischer testing of retained vials. Shipping containers for liquid presentations should maintain 2–8 °C, and frozen or lyophilized presentations should maintain −20 °C; temperature dataloggers should be placed adjacent to the product rather than in the container airspace.

Regulatory submissions should include data on master seed characterization, inactivation kinetics, residual inactivating agent removal, sterility, endotoxin, potency, and stability. Master seed characterization should include purity, biochemical profile, serotyping or genotyping, and freedom from extraneous agents according to OIE Terrestrial Manual Chapter 3.3.9 and relevant national regulations. The API is manufactured under a quality system that may follow current good manufacturing practice for veterinary medicinal products; cleanroom operations are typically performed in ISO 14644-1:2015 Grade C or better, with critical aseptic operations in Grade A laminar airflow.

What limits the use of inactivated Strain 1502 antigen in drinking-water solutions and oral premixes?

The central limitation is the absence of active mucosal invasion. Inactivated whole-cell Pasteurella multocida antigen is poorly absorbed across intact oral and respiratory mucosae when presented as a plain aqueous solution. Drinking-water administration may therefore require high antigenic mass, encapsulation, or mucosal adjuvantation. Published protection data for this specific Strain 1502 in oral solution are limited, and equivalence with injectable administration cannot be assumed. Water quality must be controlled before antigen addition: free chlorine should be neutralized, and the solution pH maintained between 6.5 and 7.5. Acidic conditions below pH 6.0 can aggregate bacterial cells and reduce filterability. Heavy metal ions and organic acids should be absent at levels that precipitate lipopolysaccharide or destabilize the cell suspension.

For tablets, capsules, granules, and premix, the main processing conflicts are heat, moisture, shear, and chemical denaturation. Direct compression is preferred over wet granulation for this heat-labile antigen. Wet granulation with water or ethanol can alter surface protein hydration and increase batch-to-batch potency variability. If wet granulation is unavoidable, the fluid-bed inlet air temperature should remain below 40 °C, and the final granulate moisture should be below 3.0% (w/w) by Karl Fischer titration. Roller compaction and slugging may be evaluated, but compaction force and dwell time must be mapped because excessive mechanical energy can disrupt bacterial cell-wall integrity and release free endotoxin, changing the safety profile of the final product.

In tablet manufacturing, a rotary tablet press with precompression capability is preferred for controlled force application. A screening range of 50–150 MPa compaction pressure is common for biological powder formulations, but the acceptable window for Strain 1502 must be established by antigen recovery testing, not inferred from placebo data. Magnesium stearate levels above 1.5% (w/w) may coat antigen particles and delay disintegration, while lower levels may cause sticking and picking on tooling. The final tablet hardness and disintegration time must be justified for the intended oral or mucosal delivery route.

For capsule filling, tamping-pin and dosator machines produce different powder-plug stresses. Tamping-pin encapsulation often generates less frictional heat but may increase fill-weight variability when the powder is cohesive. A target relative standard deviation below 5.0% for early development batches is reasonable because non-uniform antigen distribution can lead to underdosing at the flock level. Powder blends containing lyophilized antigen should be handled at 35–45% relative humidity; higher humidity can plasticize amorphous excipients and lower the blend flow function coefficient.

Veterinary Grade API specification boundaries and compendial release criteria

Release testing covers identity, sterility, inactivation, residual inactivating agent, moisture, endotoxin, and potency. Identity may be confirmed by slide agglutination using specific antisera or by polymerase chain reaction targeting conserved Pasteurella multocida loci such as kmt1. Sterility testing follows Ph. Eur. 2.6.1 or USP <71>; membrane filtration is preferred for concentrated suspensions. Inactivation is confirmed by two consecutive subcultures at 37 °C for at least 14 days in tryptose phosphate broth and on blood agar. Bacterial endotoxin is determined by the kinetic chromogenic limulus amebocyte lysate method according to Ph. Eur. 2.6.14 or USP <85>, with the limit assigned for the final target species and dose. Potency is evaluated by mouse protection test or validated ELISA according to OIE Terrestrial Manual Chapter 3.3.9; the relative potency index should be at least 1.0 against the reference vaccine unless the marketing authorization defines a different minimum.

Aqueous concentrates are standardized to a defined antigenic mass per millilitre, expressed as micrograms of cell dry weight or as opacity units. The relationship between opacity, pre-inactivation colony-forming unit equivalents, and protective antigen content must be established in the product development report. Final dosage forms cannot be interchanged on a millilitre-to-millilitre basis because adjuvants and matrix components alter adsorption and delivery kinetics. After the API is combined with aluminum hydroxide gel, particle size distribution and adsorption efficiency should be checked by centrifugation or laser diffraction according to ISO 13320-1:2020; incomplete adsorption can leave free endotoxin in the aqueous phase and increase local reactogenicity.

The API is incompatible with strong oxidizers, cationic detergents at alkaline pH, and phenol concentrations above 0.5% unless compatibility is demonstrated. It should not be mixed with high concentrations of organic acids below pH 5.5. Metal ions such as copper and zinc can bind surface proteins and destabilize lipopolysaccharide complexes; therefore, galvanized or copper equipment and containers should be avoided. Stainless-steel contact should be minimized for liquid intermediates by using disposable bioprocess bags and silicone tubing.

If the API enters a tablet or capsule line, what drying and mixing boundaries must be observed?

Process compatibility studies should start with a thermal stability assessment. Liquid concentrates and reconstituted intermediates should be held at 2–8 °C and used within the validated in-use period. Holding at 20–25 °C for more than 24 h may allow residual proteases to degrade outer membrane proteins even if sterility is maintained. Lyophilized powder may tolerate brief excursions to 25 °C, but repeated warming and cooling cycles are not recommended. Manufacturing suites should be equipped with continuous temperature monitoring and data logs for each unit operation. High-shear mixing should be avoided; a bin blender or V-blender should be filled to no more than 60–70% of nominal capacity to reduce dead zones, and the rotational speed should be limited to 10–15 rpm unless physical and potency data support higher speeds.

Dry granulation by roller compaction subjects the antigen to localized pressure. The roll speed, gap, and hydraulic pressure should be controlled, and granulated material should be milled gently through a screen not smaller than 1.0 mm to avoid excessive fines and dusting. Fine particles can segregate from the bulk blend and cause antigen non-uniformity. If the API is incorporated into an aqueous solution for later spray-coating onto granules or pellets, the coating pan inlet air temperature should be kept below 40 °C, and the spray rate should be reduced until the droplet size permits even distribution without overwetting. Overwetting can cause surface migration of soluble components and ring formation in the coating pan.

For injection formulations, the API concentrate is diluted into the final aqueous vehicle under aseptic conditions. Sterile filtration of whole-cell antigen can remove antigenic mass and is generally not recommended unless a prefilter and validated recovery step are included. Terminal heat treatment of the finished injectable is not possible; therefore, aseptic processing and sterility assurance are critical. The final injection should be tested for syringeability, resuspendability, and particle size. Aluminum hydroxide adjuvanted formulations should be gently resuspended before use; excessive shaking may disrupt flocculation and alter the sedimentation profile.

Finished injections of inactivated Strain 1502 API are usually administered intramuscularly or subcutaneously in the lower neck or breast, but injection-site reactions are a recognized constraint. The concentration of free endotoxin and the type of adjuvant influence local reactogenicity; therefore, endotoxin limits should be set for the final vaccine dose as well as the API. A target limit of ≤ 2.0 EU per vaccine dose is often used for injectable poultry vaccines, but the final value must be justified by safety studies in chicks and turkeys.

Formulation into powders, granules, premix, or solutions for oral administration should include a stability-indicating method capable of detecting antigen degradation in the presence of feed enzymes, organic acids, and mineral premixes. Feed components such as zinc oxide, copper sulfate, and calcium carbonate can alter pH or adsorb antigen; compatibility must be tested using the actual premix composition rather than a simplified buffer system. Solutions should be protected from direct sunlight and should not be stored in galvanized or copper containers. The final product should be labelled with a batch-specific antigen content and a re-test date derived from real-time stability data; accelerated stability data alone are not sufficient to justify shelf-life for heat-labile bacterial antigens.

Differences between Strain 1502 inactivated API and live or subunit Pasteurella multocida products

The principal difference is biological safety. Inactivated Strain 1502 antigen cannot revert to virulence or spread from vaccinated birds. Live attenuated Pasteurella multocida vaccines may induce mucosal responses after drinking-water or wing-web administration, but they require careful handling, may be sensitive to antibiotic use, and are generally not recommended in flocks with concurrent immunosuppressive disease. The inactivated API is therefore preferred when a flock is already under high infection pressure or when antibiotics cannot be withdrawn. However, the inactivated API alone requires more antigenic mass and an appropriate adjuvant to reach protective immunity by injection, and oral formulations may require encapsulation or mucosal adjuvants.

Subunit products based on outer membrane proteins, lipopolysaccharide, or recombinant antigens may contain fewer impurities and lower endotoxin load, but they may lack the breadth of antigenic determinants present in the whole-cell inactivated product. The whole-cell nature of Strain 1502 API preserves native surface antigens and may provide cross-protection across multiple serovars; the actual cross-protection range must be demonstrated by challenge studies. Adjuvant compatibility differs: the API can be formulated with aluminum hydroxide gel, oil-in-water emulsion, or aqueous polymer adjuvants. Aluminum hydroxide adsorption must be validated, because Pasteurella multocida lipopolysaccharide can alter flocculation and particle size distribution. Oil-based emulsions increase antigen persistence but require droplet size control, commonly 1–10 µm by laser diffraction according to ISO 13320-1:2020, and viscosity must be compatible with the intended injection device.

Compared with live vaccines, inactivated Strain 1502 antigen is more stable in a dry powder matrix, which supports its use in tablets, capsules, granules, and premix. However, the oral route for inactivated whole-cell vaccines remains less immunologically efficient than injection. Published data for this specific Strain 1502 in enteric-release tablet or capsule matrices are limited; downstream manufacturers should generate their own efficacy and safety data in the target species. The API is not a direct replacement for a licensed live vaccine or a chemically extracted subunit vaccine. Its selection depends on the target species, production system, route of administration, and regulatory region.